ERX-315-001 SITE INITIATION VISIT @TKCC

Sydney, Australia – September 4, 2024:  The Etira team, led by Founder Dr. Ganesh Raj, and the clinical Contract Research Organization Novotech successfully performed the site initiation visit at the Kinghorn Cancer Center (TKCC) in Sydney…

ERX-315 CLINICAL TRIAL APPROVED BY HREC

Dallas, TX – August 1, 2024: Etira is pleased to announce the approval of the ERX-315 Phase 1 clinical trial by the Australian Human Research Ethics Committee (HREC). This HREC approval enables the start of the clinical trial titled "A Phase…

Etira’s Australian partner MMIC expands

Melbourne, Australia - July 10, 2024:  The expansion of Etira partner Medicines Manufacturing Innovation Centre (MMIC) to the Monash Technology Precinct in Clayton was highlighted in the press. This expansion will enable further opportunities…

DECRYPTING THE OLIGO-BENZAMIDE PLATFORM

Dallas, TX – June 15, 2024: The laboratory of Etira founder Dr Jung-Mo Ahn presents a comprehensive overview of the oligo-benzamide platform that emulates a-helical peptide segments in proteins and disrupts protein-protein interactions.  Herein,…

ERX-315 SUBMITTED FOR HREC APPROVAL

Dallas, TX – May 14th, 2024: Etira is pleased to announce the submission of the regulatorydocuments for approval of administration of its breakthrough oncology drug ERX-315 to theHuman Research Ethics Committee (HREC) in Australia.…

ERX-208 potency in Ovarian Cancer

San Diego, CA. April 10, 2024: Etira founder Dr Ratna Vadlamudi’s laboratory presents comprehensive data on the activity of ERX-208 in ovarian cancer. ERX-208 is active against all four molecular subtypes of ovarian cancer and its activity…

Targeting LIPA in ovarian cancer

Dallas, TX. January 24, 2024: We are pleased to present a manuscript in Cancers from the laboratory of Etira founder Dr. Ratna Vadlamudi. The data presented show that ERX-41 targets LIPA in ovarian cancer and is effective against all 4 subtypes…

ERX-315 introduced at SABCS 2023

San Antonio, TX. December 7, 2023: Etira is pleased to present the data with its lead compound ERX-315 that cause catastrophic levels of ER stress, resulting in breast cancer cell death, and that can successfully function against multiple forms…

Independent validation of LIPA as a molecular target in TNBC

Dallas, TX. October 2, 2023: Etira is pleased to note the independent validation of LIPA as a molecular target in TNBC in a preprint in biorxiv from Dr. Esser’s group in Dusseldorf, Germany. The authors conclude that LIPA-activity is a novel…

One year later, highest almetric score for any paper published in Nature Cancer!

 Dallas, Texas. June 1, 2023:   One year after its online publication, we are pleased to note that our manuscript titled “Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid…